ROG N'un PE Oranı emsallerine kıyasla nasıldır?

ROG N, Price-To-Earnings değerine göre iyi bir değerdir. Eş ortalamaya (19x) kıyasla oran (21.3x).

ROG N'nin PE Oranı, Global Pharmaceuticals Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

ROG N Price-To-Earnings Oranı ( 19 x) baz alındığında, South American Pharmaceuticals sektör ortalamasına ( 8.7 x) kıyasla iyi bir değerdir.

ROG N'nin PE Oranı, Adil PE Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PE Oranıdır.

Değerleme analizi için ROG N 'in Price-To-Earnings Adil Oranını hesaplamak için yeterli veri yok.

Gelecekteki nakit akışlarına bakıldığında ROG N 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

ROG N ( MX$5833.34 ) [[adil değer]] tahminimizin altında işlem görüyor ( MX$12887.08 )

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Hedef fiyat, mevcut hisse senedi fiyatından % 20 daha az yüksektir.

Roche Holding (BMV:ROG N) - Hisse Senedi Fiyatı, Haberler ve Analizler

ROG N Stoklara Genel Bakış

Roche Holding AG, Avrupa, Kuzey Amerika, Latin Amerika, Asya, Afrika, Avustralya ve Okyanusya'da ilaç ve diagnostik alanlarında faaliyet göstermektedir. Daha fazla detay

ROG N temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	5/6

Ödüller

Adil değer tahminimizden 54.7% daha düşük bir oranda işlem görüyor

Kazançların yılda 11.15% oranında artması öngörülüyor

3.79% oranında güvenilir bir temettü öder

Risk Analizi

Hisse senetleri oldukça likit değildir

Yüksek borç seviyesine sahip

Finansal sonuçları etkileyen büyük tek seferlik kalemler

Roche Holding AG Rakipler

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.9b

Novartis

SWX:NOVN

CHF 183.8b

Merck

NYSE:MRK

US$250.9b

AstraZeneca

LSE:AZN

UK£162.4b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Roche Holding
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CHF 5,833.34
52 Haftanın En Yüksek Seviyesi	CHF 6,580.00
52 Haftanın En Düşük Seviyesi	CHF 4,000.08
Beta	0.15
11 Aylık Değişim	-6.26%
3 Aylık Değişim	-9.79%
1 Yıllık Değişim	28.27%
33 Yıllık Değişim	-30.69%
5 Yıllık Değişim	-2.79%
Halka arzdan bu yana değişim	66.03%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	ROG N	MX Pharmaceuticals	MX Pazar
7D	0%	-2.5%	-1.0%
1Y	28.3%	-17.5%	-3.3%

Getiri vs. Endüstri: ROG N geçen yıl % -17.5 oranında getiri sağlayan MX Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: ROG N geçen yıl % -3.3 oranında getiri sağlayan MX Piyasasını aştı.

Fiyat Oynaklığı

Is ROG N's price volatile compared to industry and market?
ROG N volatility
ROG N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	6.1%
10% least volatile stocks in MX Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: ROG N hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ROG N 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1896	103,605	Thomas Schinecker	www.roche.com

Roche Holding AG, Avrupa, Kuzey Amerika, Latin Amerika, Asya, Afrika, Avustralya ve Okyanusya'da ilaç ve diagnostik işleriyle uğraşmaktadır. Şirket, anemi, kan ve solid tümörler, dermatoloji, hemofili, enflamatuar ve otoimmün, nörolojik bozukluklar, oftalmoloji, solunum bozuklukları ve transplantasyon terapötik alanlarında farmasötik ürünler sunmaktadır. Ayrıca çeşitli terapötik alanlar için ürünler geliştirmektedir.

Roche Holding AG Temel Bilgiler Özeti

Roche Holding'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ROG N temel i̇stati̇sti̇kler
Piyasa değeri	Mex$4.68t
Kazançlar(TTM)	Mex$243.39b
Gelir(TTM)	Mex$1.39t

19.0x

F/K Oranı

3.3x

P/S Oranı

ROG N aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ROG N gelir tablosu (TTM)
Gelir	CHF 60.58b
Gelir Maliyeti	CHF 15.43b
Brüt Kâr	CHF 45.16b
Diğer Giderler	CHF 34.54b
Kazançlar	CHF 10.62b

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	13.33
Brüt Marj	74.54%
Net Kâr Marjı	17.53%
Borç/Özkaynak Oranı	104.8%

ROG N uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

3.8%

Mevcut Temettü Verimi

72%

Ödeme Oranı

ROG N Stoklara Genel Bakış

Ödüller

Risk Analizi

Roche Holding AG Rakipler

BMV:LAB B

Mex$24.9b

SWX:NOVN

CHF 183.8b

NYSE:MRK

US$250.9b

LSE:AZN

UK£162.4b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Recent updates

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

Investor sentiment improves as stock rises 15%

New minor risk - Earnings quality

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

First half 2024 earnings released: EPS: CHF7.85 (vs CHF8.93 in 1H 2023)

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Investor sentiment improves as stock rises 18%

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Dividend of CHF9.60 announced

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Full year 2023 earnings released: EPS: CHF14.39 (vs CHF15.53 in FY 2022)

Dividend of CHF9.60 announced

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration